Figure 1. Change rate in serum indicated that patients with significantly reduced PDGF-BB had a much improved prognosis than the raised and slightly reduced group in both progression-free survival (A, C and E) and overall survival (B, D and F) either for the 50 patients that received radical radiotherapy (A and B) or for the remaining 18 patients that received neoadjuvant radiotherapy and surgery (C and D). In addition, regarding the entire 68 cases taken together (E and F), it also has statistical significance.